In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Bayer Schering Pharma, OncoMed ally in cancer stem cells

Executive Summary

Bayer Schering Pharma AG and cancer-focused OncoMed Pharmaceuticals Inc. will collaborate to identify and develop up to five new stem cell therapeutics--antibodies, proteins, and/or small molecules--that target the Wnt signaling pathway, which is thought to be critical to the growth and survival of cancer.
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R+D and Marketing-Licensing
    • Includes Contract

Related Companies

Advertisement
UsernamePublicRestriction

Register